Meldola

• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom … Ended
  2024-512848-30-00 4 2024-11-12 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
• An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budig … Ended
  2023-508356-19-00 4 2024-06-25 Pancreatic adenocarcinoma metastatic
• A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended
  2023-507324-23-00 4 2024-05-22 recurrent or persistent uterine serous carcinoma
• [68Ga]Ga-PentixaFor-PET imaging for staging of marginal zone lymphoma Ended
  2022-500918-25-00 5 2024-05-20 Marginal Zone Lymphoma
• A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended
  2023-503223-26-00 9 2024-05-07 Advanced Solid Tumors Harboring a KRASG12C Mutation
• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of vepdegestrant (ARV-471) in Combination With Other Medicines … Ended
  2023-507125-41-00 9 2024-03-25 Advanced or Metastatic Breast Cancer
• A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 … Ended
  2023-506092-10-00 4 2024-03-11 Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous
• A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to te … Ended
  2022-502467-38-00 4 2024-02-22 Non-small cell lung cancer (NSCLC)
• A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended
  2022-503013-32-00 4 2024-01-29 ER-positive/HER2-negative early breast cancer
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 Relapsed or Refractory High-Risk Myelodysplastic Syndrome
• A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hemato … Ended
  2022-502672-23-00 3 2023-10-18 Richter's Syndrome
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV … Ended
  2022-502620-49-00 2 2023-08-01 Resected Melanoma Stage III or Stage IV
• A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended
  2022-500177-13-00 4 2023-06-02 Metastatic Colorectal Cancer (mCRC)
• A Phase I study to evaluate the safety and dosimetry of 68Ga-labelled OncoFAP derivatives in patients with solid tumors Ended
  2022-500902-16-00 1 2023-04-27 Patients with breast cancer, colorectal cancer, oesophageal cancer and
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi … Ended
  2022-500652-37-00 4 2022-12-01 Advanced melanoma refractory to prior checkpoint inhibitor therapy
• Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat … Ended
  2024-514714-12-00 10 2022-11-11 Metastatic Pancreatic Ductal Adenocarcinoma
• A clinical study conducted to evaluate the safety, efficacy and tolerability of a drug called liposomal annamycin administered with cytarabi … Ended
  2024-516388-10-00 9 2022-09-23 Acute Myeloid Leukemia
• Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovari … Ended
  2024-516166-11-00 5 2022-06-06 Platinum resistant recurrent or metastatic ovarian, fallopian, or prim
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• A study to compare Onivyde manufactured at two different production sites in adult participants with advanced cancer in the pancreas Ended
  2024-516760-28-00 2 2022-05-04 Metastatic Pancreatic Adenocarcinoma

Showing 385–408 of 447 trials